title: Borderline ovarian tumours: clinical analysis of 38 cases.
abstract: Thirty-eight patients with ovarian tumours of low malignant potential (borderline) were diagnosed and treated in Tehran University Gynecology Oncology Department from 1991 to 2002, and have been reviewed. In this study age, clinical behavior, symptoms, surgical stage, type of tumour, surgery, adjuvant treatment, survival and recurrences were evaluated. A retrospective chart review was performed on these 38 patients who were treated for histopathologically confirmed tumours of low malignant potential between 1991-2002. The mean age was 34.4 years, range (14-83) (SD: 18.33). Post surgical FIGO staging was: Stage I=93.75%, stage III 6.25%. Histologic subtypes were: Serous 76.31% (29 patients), Mucinous 21.05% (8 patients), Mixed types 2.63% (1 patient). Mean pre-operative CA125 value was 114.90 (SD: +/- 90.30). Thirty-three percent of patients had only a simple cyst in ultrasonography. Conservative surgery was performed in 76.32% (29 patients). More radical surgery (TAH + BSO) was performed in 9 patients (23.68%). There were 6 recurrences. Three patients with recurrence and invasive implants received chemotherapy and secondary surgery was performed. Survival rate was 100% at 3 years for all stages and 89% at 5 years. One patient died of recurrent disease at 48 months after initial diagnosis. Our data suggest that LMP tumours are most frequently diagnosed in stage I. Most common histological type was serous, and 5 of the recurrences of (6 patients) were initially diagnosed at stage I, and had been treated with conservative surgery with no adjuvant therapy.
authors.affiliation: Department of Gynecology and Oncology, Tehran University of Medical Sciences, Tehran, Iran. valrec2@yahoo.com
authors.forename: N
authors.initials: N
authors.lastname: Behtash
authors.forename: M
authors.initials: M
authors.lastname: Modares
authors.forename: M
authors.initials: M
authors.lastname: Abolhasani
authors.forename: F
authors.initials: F
authors.lastname: Ghaemmaghami
authors.forename: M
authors.initials: M
authors.lastname: Mousavi
authors.forename: F
authors.initials: F
authors.lastname: Yarandi
authors.forename: P
authors.initials: P
authors.lastname: Hanjani
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D003131:Combined Modality Therapy; D018282:Cystadenocarcinoma, Mucinous / Q000175:diagnosis / Q000453:epidemiology* / Q000628:therapy; D018284:Cystadenocarcinoma, Serous / Q000175:diagnosis / Q000453:epidemiology* / Q000628:therapy; D005260:Female; D006801:Humans; D007492:Iran / Q000453:epidemiology; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000175:diagnosis / Q000453:epidemiology* / Q000628:therapy; D010052:Ovariectomy / Q000379:methods; D012189:Retrospective Studies